Get the Daily Brief

All action, no filler. BioBriefs delivers biotech’s 10 must-know updates, every morning.

Latest Biotech News

AbbVie Pays $700M for IGI’s Trispecific Multiple Myeloma Antibody

July 12, 2025

AbbVie has secured global rights to IGI Therapeutics’ early-stage trispecific antibody, ISB-2001, targeting BCMA, CD38, and CD3 for multiple myeloma treatment. The $700 million upfront deal could...

Capricor’s Duchenne Muscular Dystrophy Cell Therapy Faces FDA Setback

July 12, 2025

Capricor Therapeutics has received a complete response letter (CRL) from the FDA rejecting its Biologics License Application (BLA) for deramiocel, an off-the-shelf cell therapy aimed at treating...

AI Models Revolutionize Cell Biology and Drug Discovery

July 12, 2025

Researchers from Columbia University and the Chan Zuckerberg Initiative have developed GREmLN, an AI-based virtual cell model that captures complex gene regulatory networks. Utilizing graph-based...

Soleno’s Rare Disease Drug Surges Past Expectations in Q2

July 12, 2025

Soleno Therapeutics’ first-quarter sales of Vykat XR, a treatment for the insatiable hunger in Prader-Willi syndrome, exceeded market forecasts with $31–33 million in net revenues. The launch...

Nuclidium and Actithera Lead New Wave in Radiopharmaceuticals Funding

July 12, 2025

The European radiopharma sector gains momentum as Nuclidium AG closed a CHF 79 million ($99 million) Series B funding round, advancing clinical development of copper isotope-based diagnostics and...

Advances in Antibody and Protein Engineering Platforms

July 12, 2025

Emerging technologies are shaping antibody and protein engineering: Cellecta introduced DriverMap scAIR kits enabling detailed T and B cell receptor sequencing at single-cell resolution without...

Jazz Pharmaceuticals Names Renée Galá as New CEO

July 12, 2025

Jazz Pharmaceuticals announced that its current President and Chief Operating Officer, Renée Galá, will succeed CEO and co-founder Bruce Cozadd, effective August 11. This leadership change follows...

Merck Acquires Verona Pharma in $10 Billion Deal for COPD Pipeline

July 11, 2025

Merck & Co. announced the acquisition of Verona Pharma for $10 billion, aiming to enhance its portfolio in cardio-pulmonary disease treatments with the inclusion of Verona's COPD drug, Ohtuvayre....

FDA Publishes Rejection Letters to Improve Transparency in Drug Approvals

July 11, 2025

In an unprecedented move, the FDA has released an initial batch of over 200 complete response letters (CRLs) issued from 2020 to 2024, offering insight into deficiencies cited in drug approval...

FDA Rejects Capricor’s Cell Therapy for Duchenne Muscular Dystrophy

July 11, 2025

The FDA issued a complete response letter (CRL) to Capricor Therapeutics, rejecting their biologics license application for deramiocel, a cell therapy aimed at treating cardiomyopathy in Duchenne...

AbbVie Inks $700 Million Deal for Trispecific Antibody in Multiple Myeloma

July 11, 2025

AbbVie has acquired global rights to a trispecific antibody, ISB-2001, from IGI Therapeutics for $700 million upfront, with potential milestone and royalty payments reaching nearly $2 billion. The...

Launch of Center for Pediatric CRISPR Therapies Funded by CZI and IGI

July 11, 2025

The Chan Zuckerberg Initiative and the Innovative Genomics Institute have jointly funded a new Center for Pediatric CRISPR Cures with a $20 million grant. The center aims to advance personalized...

New AI Models Advance Prediction of Cell and Protein Dynamics

July 11, 2025

Innovative AI platforms are reshaping biological modeling, improving insights into cell behavior and protein dynamics essential for drug discovery. The GREmLN model developed by Columbia...

Soleno Therapeutics Reports Strong Early Sales for Prader-Willi Syndrome Drug

July 11, 2025

Soleno Therapeutics’ Vykat XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome, has exceeded expectations in its initial full-quarter sales, with net revenues projected...

Nuclidium and Actithera Secure Significant Funding to Fuel Radiopharmaceutical Development

July 11, 2025

European radiopharmaceutical companies Nuclidium AG and Actithera A/S have attracted substantial venture capital to progress clinical development efforts. Nuclidium closed a CHF79 million ($99...

Jazz Pharmaceuticals Names Renee Galá as New CEO Amid Leadership Transition

July 11, 2025

Jazz Pharmaceuticals has appointed Renee Galá, its current president and chief operating officer, as the next CEO effective August 11, 2025. Galá succeeds co-founder Bruce Cozadd, who plans to...

Merck Boosts Respiratory Portfolio with $10B Verona Pharma Buyout

July 11, 2025

Merck & Co. announced the acquisition of Verona Pharma for $10 billion, securing Ohtuvayre, a novel maintenance treatment for chronic obstructive pulmonary disease (COPD). Ohtuvayre combines...

FDA Publishes First Batch of Drug Rejection Letters in Transparency Move

July 11, 2025

In an unprecedented policy shift, the FDA made public an initial set of over 200 complete response letters (CRLs) issued to drug sponsors between 2020 and 2024. These letters detail the agency’s...

FDA Rejects Capricor’s Cell Therapy for Duchenne Muscular Dystrophy

July 11, 2025

The FDA issued a Complete Response Letter rejecting Capricor Therapeutics' application for approval of deramiocel, an allogeneic cell therapy for cardiomyopathy in Duchenne muscular dystrophy...

Pfizer and Astellas Show Combo Therapy Boost in Early Prostate Cancer Survival

July 11, 2025

Pfizer and Astellas released positive Phase 3 data from their Embark trial demonstrating that combining Xtandi (enzalutamide) with leuprolide significantly improves overall survival for men with...